FOLH1 and posterior cortical atrophy: 177Lu-PSMA targets PSMA, a protein highly expressed in PCa cells, leading to improved patient outcomes with a prostate-specific antigen (PSA) response rate of 60-70% and a median progression-free survival of about eight months [3-5].